Kestra Medical reports multiple 15,000-share Form 144 dispositions

Kestra Medical Technologies, Ltd. reported Form 144 filings showing proposed and completed dispositions of 15,000 common shares under an issuer equity compensation plan.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. reported Form 144 filings showing proposed and completed dispositions of 15,000 common shares under an issuer equity compensation plan. The filing lists a restricted share issuance dated 01/21/2026 and multiple sales by Brian Webster of 15,000 shares each on 02/17/2026, 03/17/2026, 04/15/2026 and 05/15/2026, with dollar amounts shown per trade.

Insights

Insider Transactions Analyst

Form 144 discloses multiple 15,000-share dispositions by a reporting person.

The filing lists a restricted share issuance of 15,000 common shares dated 01/21/2026 granted under an issuer equity compensation plan. It also documents four separate sales by Brian Webster of 15,000 shares on 02/17/2026, 03/17/2026, 04/15/2026, and 05/15/2026, each with an associated dollar figure in the excerpt.

These entries are routine compliance disclosures of dispositions; the filing does not link the proceeds to the issuer or state any trading plan. Subsequent filings would be needed to show total post-transaction holdings or confirm the cash‑flow treatment.

Key Figures

Restricted issuance: 15,000 shares Sale on 02/17/2026: 15,000 shares Sale on 03/17/2026: 15,000 shares +2 more

5 metrics

Restricted issuance 15,000 shares granted as part of issuer equity compensation plan on <date>01/21/2026</date>

Sale on 02/17/2026 15,000 shares reported sale by Brian Webster with amount $384,020.06

Sale on 03/17/2026 15,000 shares reported sale by Brian Webster with amount $304,123.49

Sale on 04/15/2026 15,000 shares reported sale by Brian Webster with amount $300,671.04

Sale on 05/15/2026 15,000 shares reported sale by Brian Webster with amount $314,329.85

Key Terms

Form 144, restricted share issuance, issuer equity compensation plan

3 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

restricted share issuance financial

"Restricted share issuance | KESTRA MEDICAL TECHNOLOGIES, LTD."

issuer equity compensation plan financial

"Granted as part of issuer equity compensation plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kestra Medical Technologies (KMTS) Form 144 show?

It shows a restricted issuance of 15,000 common shares dated 01/21/2026 and multiple reported dispositions of 15,000 shares by Brian Webster on specific dates in 2026.

Who reported the share sales in the KMTS Form 144?

The sales are reported by Brian Webster, with transactions recorded on 02/17/2026, 03/17/2026, 04/15/2026, and 05/15/2026 for 15,000 shares each.

Were the shares granted under a compensation plan?

Yes. The filing references a restricted share issuance granted as part of an issuer equity compensation plan dated 01/21/2026 for 15,000 shares.

Do the dollar figures in the filing indicate proceeds?

The excerpt lists dollar amounts alongside each sale (for example, $384,020.06 on 02/17/2026), presented as per‑transaction figures in the filing excerpt.

Does this Form 144 disclose remaining holdings after the sales?

No. The provided excerpt documents the issuance and individual sales with dates and amounts but does not state total shares held after these transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001877188
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Webster Brian Daniel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	15000	312142.94	58373353	06/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	01/21/2026	Restricted share issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			15000	01/21/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	02/17/2026	15000	384020.06
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	03/17/2026	15000	304123.49
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	04/15/2026	15000	300671.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	05/15/2026	15000	314329.85

144: Remarks and Signature

Remarks
Date of Notice	06/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Brian Webster
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)